RAPP on Nasdaq
Rapport Therapeutics, Inc.
American pharmaceutical preparations company, incorporated in Delaware.
Price unavailable
Last updated Oct 18, 2026.
Overview
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Research and development | $94.8M | $60.9M |
| General and administrative | $30.3M | $22.1M |
| Total operating expenses | $125.1M | $83.1M |
| Loss from operations | -$125.1M | -$83.1M |
| Interest income | $13.6M | $12.1M |
| Change in fair value of preferred stock tranche right liability | $0 | -$7.4M |
| Total other income, net | $13.6M | $4.7M |
| Net loss | -$111.5M | -$78.3M |
| Net loss per share attributable to common stockholders, basic | -$2.86 | -$3.78 |
| Net loss per share attributable to common stockholders, diluted | -$2.86 | -$3.78 |
| Weighted-average common shares outstanding, basic | 38.9M shares | 20.7M shares |
| Weighted-average common shares outstanding, diluted | 38.9M shares | 20.7M shares |
| Change in unrealized gains (losses) on investments, net of tax | $1.1M | -$526.0K |
| Total other comprehensive income (loss) | $1.1M | -$526.0K |
| Comprehensive loss | -$110.4M | -$78.8M |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2024-05-31 | 2023-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $52.6M | $56.8M | ||
| Short-term investments | $437.9M | $248.5M | ||
| Restricted cash | $105.0K | $105.0K | ||
| Prepaid expenses and other current assets | $7.9M | $4.4M | ||
| Total current assets | $498.6M | $309.8M | ||
| Property and equipment, net | $3.0M | $3.5M | ||
| Operating lease right of use asset, net | $9.9M | $1.4M | ||
| Other assets | $985.0K | $160.0K | ||
| Total assets | $512.4M | $314.9M | ||
| Accounts payable | $4.2M | $2.0M | ||
| Accrued expenses and other current liabilities | $12.1M | $6.1M | ||
| Operating lease liability | $2.8M | $737.0K | ||
| Total current liabilities | $19.0M | $8.8M | ||
| Operating lease liability, net of current portion | $8.7M | $739.0K | ||
| Total liabilities | $27.8M | $9.5M | ||
| Undesignated preferred stock, $0.001 par value; 10,000,000 shares authorized at December 31, 2025 and December 31, 2024, respectively; zero shares issued and outstanding at December 31, 2025 and December 31, 2024 | $0 | $0 | ||
| Common stock, $0.001 par value; 500,000,000 shares authorized at December 31, 2025 and December 31, 2024; 47,772,567 shares and 36,580,202 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | $48.0K | $37.0K | ||
| Additional paid-in capital | $719.3M | $429.7M | ||
| Accumulated other comprehensive income (loss) | $546.0K | -$522.0K | ||
| Accumulated deficit | -$235.2M | -$123.7M | ||
| Total stockholders' equity | $484.7M | $305.4M | -$25.6M | |
| Total liabilities and stockholders' equity | $512.4M | $314.9M | ||
| Undesignated preferred stock, par value | $0.00 | $0.00 | $0.00 | |
| Undesignated preferred stock, shares authorized | 10.0M shares | 10.0M shares | 10.0M shares | |
| Undesignated preferred stock, shares issued | 0 shares | 0 shares | ||
| Undesignated preferred stock, shares outstanding | 0 shares | 0 shares | ||
| Common stock, par value | $0.00 | $0.00 | ||
| Common stock, shares authorized | 500.0M shares | 500.0M shares | ||
| Common stock, shares issued | 47.8M shares | 36.6M shares | ||
| Common stock, shares outstanding | 47.8M shares | 36.6M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2024-05-31 | 2023-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $52.6M | $56.8M | ||
| Short-term investments | $437.9M | $248.5M | ||
| Restricted cash | $105.0K | $105.0K | ||
| Prepaid expenses and other current assets | $7.9M | $4.4M | ||
| Total current assets | $498.6M | $309.8M | ||
| Property and equipment, net | $3.0M | $3.5M | ||
| Operating lease right of use asset, net | $9.9M | $1.4M | ||
| Other assets | $985.0K | $160.0K | ||
| Total assets | $512.4M | $314.9M | ||
| Accounts payable | $4.2M | $2.0M | ||
| Accrued expenses and other current liabilities | $12.1M | $6.1M | ||
| Operating lease liability | $2.8M | $737.0K | ||
| Total current liabilities | $19.0M | $8.8M | ||
| Operating lease liability, net of current portion | $8.7M | $739.0K | ||
| Total liabilities | $27.8M | $9.5M | ||
| Undesignated preferred stock, $0.001 par value; 10,000,000 shares authorized at December 31, 2025 and December 31, 2024, respectively; zero shares issued and outstanding at December 31, 2025 and December 31, 2024 | $0 | $0 | ||
| Common stock, $0.001 par value; 500,000,000 shares authorized at December 31, 2025 and December 31, 2024; 47,772,567 shares and 36,580,202 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | $48.0K | $37.0K | ||
| Additional paid-in capital | $719.3M | $429.7M | ||
| Accumulated other comprehensive income (loss) | $546.0K | -$522.0K | ||
| Accumulated deficit | -$235.2M | -$123.7M | ||
| Total stockholders' equity | $484.7M | $305.4M | -$25.6M | |
| Total liabilities and stockholders' equity | $512.4M | $314.9M | ||
| Undesignated preferred stock, par value | $0.00 | $0.00 | $0.00 | |
| Undesignated preferred stock, shares authorized | 10.0M shares | 10.0M shares | 10.0M shares | |
| Undesignated preferred stock, shares issued | 0 shares | 0 shares | ||
| Undesignated preferred stock, shares outstanding | 0 shares | 0 shares | ||
| Common stock, par value | $0.00 | $0.00 | ||
| Common stock, shares authorized | 500.0M shares | 500.0M shares | ||
| Common stock, shares issued | 47.8M shares | 36.6M shares | ||
| Common stock, shares outstanding | 47.8M shares | 36.6M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$111.5M | -$78.3M |
| Depreciation and amortization | $1.0M | $839.0K |
| Net (accretion) and amortization of investments in marketable securities | -$1.4M | -$3.2M |
| Change in fair value of preferred stock tranche right liability | $0 | $7.4M |
| Non-cash lease expense | $2.0M | $642.0K |
| Stock-based compensation expense | $18.9M | $10.2M |
| Prepaid expenses and other current assets | -$3.6M | -$1.9M |
| Other assets | -$791.0K | $83.0K |
| Accounts payable | $2.2M | -$346.0K |
| Accrued expenses and other current liabilities | $6.2M | $371.0K |
| Operating lease liabilities | -$491.0K | -$670.0K |
| Net cash used in operating activities | -$87.5M | -$64.8M |
| Purchases of short-term investments | -$354.8M | -$377.5M |
| Maturities of short-term investments | $167.9M | $209.8M |
| Purchases of property and equipment | -$616.0K | -$2.4M |
| Net cash used in investing activities | -$187.5M | -$170.1M |
| Proceeds from initial public offering and concurrent private placement, net of underwriter discounts and commissions and deferred offering costs | $157.7M | |
| Proceeds from underwritten public offering, net of underwriter discounts and commissions and deferred offering costs | $269.4M | |
| Proceeds from exercise of stock options | $1.3M | $7.0K |
| Repurchase of unvested restricted common stock | -$1.0K | |
| Net cash provided by financing activities | $270.8M | $221.6M |
| Net (decrease) increase in cash, cash equivalents, and restricted cash | -$4.2M | -$13.3M |
| Right-of-use assets obtained in exchange for operating lease liabilities | $10.5M | |
| Offering costs included in accounts payable and accrued expenses at period end | $35.0K | |
| Purchases of property and equipment included in accounts payable and accrued expenses at period end | $20.0K | $172.0K |
No quarter-by-quarter statement was filed.
Leadership
Who has led Rapport Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
Chief operating officer
2025
- Chief executive officerAbraham Ceesay Jun 6, 2024 to now7
- Chief financial officerTroy A. Ignelzi Jun 6, 2024 to now8
- Chief operating officerCheryl Gault Feb 4, 2025 to now9
Board members and other officers (15)
- Chief Medical OfficerJeffrey Sevigny Mar 5, 2025 to now10
- Chief Medical OfficerBradley S. Galer Jun 6, 2024 to Jun 10, 202411
- Chief Operations OfficerCheryl Gault Jun 6, 2024 to Jun 10, 202412
- Chief Scientific OfficerDavid Bredt Jun 6, 2024 to now13
- Chief Development OfficerKrishnaswamy Yeleswaram Jun 6, 2024 to now14
- Board memberAbraham Ceesay Jun 6, 2024 to now7
- Board memberJames Healy Jun 6, 2024 to now15
- Board memberJeffrey K. Tong Jun 6, 2024 to Jun 6, 202416
- Board memberJohn Maraganore Jun 6, 2024 to now17
- Board memberReid M. Huber Jun 6, 2024 to now18
- Board memberTerry-Ann Burrell Jun 6, 2024 to Jun 6, 202419
- Board memberPaul M. Silva Nov 7, 2024 to now20
- Board memberRamiro Sanchez Nov 7, 2024 to now21
- Board memberRobert J. Perez Nov 7, 2024 to now22
- Board memberWendy B. Young Nov 7, 2024 to now23
Timeline
- Jun 6, 2024New chief executive Abraham Ceesay becomes CEO7
Filings
229 filings to the SEC since October 2021: 2 annual reports, 7 quarterly reports, 21 major events, 111 insider forms, 18 large holders, 70 other. The latest 20:
- Oct 8, 20264 EDGAR
- Oct 6, 2026144 EDGAR
- Oct 1, 20264 EDGAR
- Sep 30, 2026144 EDGAR
- Sep 24, 20264 EDGAR
- Sep 9, 20264 EDGAR
- Aug 26, 20264 EDGAR
- Aug 26, 20264 EDGAR
- Aug 25, 2026144 EDGAR
- Aug 24, 2026144 EDGAR
- Aug 20, 20264 EDGAR
- Aug 19, 2026144 EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 12, 2026SCHEDULE 13G/A EDGAR
- Aug 12, 20264 EDGAR
- Aug 5, 202610-Q EDGAR
- Aug 5, 20268-K EDGAR
- Jul 29, 20264 EDGAR
- Jul 15, 20264 EDGAR
The 229 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last three years, summarized. The full record is on SEC EDGAR.
Insider trades and holders
Large holders
Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 18 such filings since October 2021, the latest 10:
- Aug 14, 2026SCHEDULE 13G/A
- Aug 14, 2026SCHEDULE 13G/A
- Aug 12, 2026SCHEDULE 13G/A
- May 15, 2026SCHEDULE 13G/A
- Feb 17, 2026SCHEDULE 13G/A
- Jan 21, 2026SCHEDULE 13G
- Nov 14, 2025SCHEDULE 13G/A
- Oct 22, 2025SCHEDULE 13G/A
- Sep 18, 2025SCHEDULE 13D/A
- Feb 13, 2025SCHEDULE 13G
From Forms 4 and Schedules 13D and 13G filed with the SEC.
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Fmr LLC | 7,172,894 | $298.9M | 0.0% | +3,955 |
| Trv Gp V, LLC | 6,280,525 | $261.7M | 52.5% | −854,708 |
| ARCH Venture Management, LLC | 3,728,738 | $155.4M | 14.1% | No change |
| Capital International Investors | 2,921,958 | $121.8M | 0.0% | −176,015 |
| Goldman Sachs Group Inc | 2,910,449 | $121.3M | 0.0% | −31,802 |
| BlackRock, Inc. | 2,699,786 | $112.5M | 0.0% | +193,831 |
| Cormorant Asset Management, LP | 2,657,521 | $110.7M | 5.7% | −300,000 |
| Sofinnova Investments, Inc. | 1,904,408 | $79.4M | 4.2% | No change |
| Johnson & Johnson | 1,784,517 | $74.4M | 9.3% | No change |
| Polar Capital Holdings Plc | 1,608,514 | $67.0M | 0.2% | −33,947 |
| Baker Bros. Advisors LP | 1,547,090 | $64.5M | 0.3% | No change |
| Vanguard Capital Management LLC | 1,346,512 | $56.1M | 0.0% | +21,430 |
| Trv Gp Vi, LLC | 969,218 | $40.4M | 17.4% | No change |
| State Street Corp | 818,712 | $34.1M | 0.0% | +59,160 |
| Geode Capital Management, LLC | 793,453 | $33.1M | 0.0% | +71,831 |
| Perceptive Advisors LLC | 773,342 | $32.2M | 0.5% | +99,419 |
| Vestal Point Capital, LP | 730,000 | $30.4M | 0.7% | −706,229 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 644,082 | $26.8M | 0.0% | −274,784 |
| Siren, L.L.C. | 641,469 | $26.7M | 0.5% | No change |
| Capital World Investors | 551,657 | $23.0M | 0.0% | +15,050 |
| Alliancebernstein L.P. | 693,384 | $21.7M | 0.0% | −34,459 |
| Dimensional Fund Advisors LP | 362,114 | $15.1M | 0.0% | +137,616 |
| Vanguard Portfolio Management LLC | 359,944 | $15.0M | 0.0% | +39,035 |
| Candriam S.C.A. | 347,650 | $14.5M | 0.1% | +161,725 |
| Sio Capital Management, LLC | 307,657 | $12.8M | 2.2% | −59,152 |
13F reports cover disclosed long positions in U.S. stocks only.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15SEC EDGARJames Healy, Board member
- 16SEC EDGARJeffrey K. Tong, Board member
- 17SEC EDGARJohn Maraganore, Board member
- 18SEC EDGARReid M. Huber, Board member
- 19SEC EDGARTerry-Ann Burrell, Board member
- 20SEC EDGARPaul M. Silva, Board member
- 21SEC EDGARRamiro Sanchez, Board member
- 22SEC EDGARRobert J. Perez, Board member
- 23SEC EDGARWendy B. Young, Board member